Table 1: Clinical characteristics at presentation of 100 new crystal proven gout patients.
| Males, n = 88, age, mean ± SD | 62.1 ± 13.1 years |
| Females, n = 12, age, mean ± SD | 74.1 ± 6.9 years |
| Disease duration, mean ± SD | 8.6 ± 6.9 years |
| Disease pattern | Disease duration, mean ± SD |
| • Monoarticular disease (n = 18) | 1.5 ± 6.2 years* |
| • Oligoarticular disease (n = 37) | 6.8 ± 6.9 years* |
| • Polyarticular disease (n = 25) | 11.3 ± 6.6 years* |
| • Tophaceous disease (n = 20) | 12.3 ± 8.1 years* |
| Podagra ever (n = 100) | 74% |
| Urate Lowering Treatment ever (n = 100) | 42% |
| Urate Lowering Treatment at entry (n = 100) | 15% |
| Distribution of affected joints | |
| Metatarsal-phalangeal joints (n = 100) | 63% |
| Midfoot/ankles (n = 100) | 57% |
| Knees (n = 100) | 57% |
| Hands/wrists/elbows (n = 100) | 47% |
| Ultrasonic findings | Double contour ISHE |
| All (n = 94) | 73% 68% |
| Monoarticular (n = 18) | 50% 38%¶ |
| Oligoarticular (n = 36) | 75% 64%¶ |
| Polyarticular (n = 21) | 76% 84%¶ |
| Tophaceous (n = 19) | 74% 100%¶ |
| Serum-Urate | |
| With ULT (Allopurinol) (n = 15), mean ± SD | 7.7 ± 1.7 mg/dl (0.46 ± 0.10 mmol/l) |
| Without ULT (n = 85), mean ± SD | 8.9 ± 1.9 mg/dl (0.53 ± 0.11 mmol/l) |
| • Monoarticular (n = 15) | 8.4 ± 1.7 mg/dl (0.50 ± 0.10 mmol/l)# |
| • Oligoarticular (n = 34) | 8.7 ± 1.7 mg/dl (0.52 ± 0.10 mmol/l)# |
| • Polyarticular (n = 22) | 9.3 ± 2.2 mg/dl (0.55 ± 0.13 mmol/l)# |
| • Tophaceous (n = 14) | 9.8 ± 1.7 mg/dl (0.58 ± 0.10 mmol/l)# |
ULT: Urate Lowering Therapy; ISHE: Intra-Synovial Hyper-Echoic areas;*Spearman's σ: 0.466, P < 0.001.
¶Spearman's σ: 0.400, P < 0.001. #Spearman's σ: 0.247, P < 0.05.